P53-Mdm2 Pathway: Evidences for a New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia

Frontiers in Pharmacology - Switzerland
doi 10.3389/fphar.2016.00491
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Frontiers Media SA

Related search

CD19-Targeted Nanodelivery of Doxorubicin Enhances Therapeutic Efficacy in B-Cell Acute Lymphoblastic Leukemia

Molecular Pharmaceutics
Drug DiscoveryMolecular MedicinePharmaceutical Science
2015English

BCL-2 Is a Therapeutic Target for Hypodiploid B-Lineage Acute Lymphoblastic Leukemia

Cancer Research
Cancer ResearchOncology
2019English

Epigenetic Inactivation of Notch-Hes Pathway in Human B-Cell Acute Lymphoblastic Leukemia

PLoS ONE
Multidisciplinary
2013English

Integrin Alpha4 as a Therapeutic Target of Acute Lymphoblastic Leukemia

Journal of Blood Disorders & Transfusion
2014English

miRNAs in Acute Lymphoblastic Leukemia: Diagnosis, Prognosis and Target Therapeutic

2019English

KLF5 Interacts With P53 in Regulating Survivin Expression in Acute Lymphoblastic Leukemia

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2006English

Evolution of the P53-Mdm2 Pathway

BMC Evolutionary Biology
EvolutionEcologySystematicsBehavior
2017English

Acute Lymphoblastic Leukemia

2016English

Acute Lymphoblastic Leukemia

2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy